4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Premature Ovarian Failure by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 50 ongoing clinical trials involving Premature Ovarian Failure
Of the 50 trials,24 trials are in Phase II
Furthermore, 10 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Premature Ovarian Failure by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Premature Ovarian Failure, a Women's Health condition. The largest number of ongoing clinical trials for Premature Ovarian Failure is conducted in the Asia-Pacific region. Middle East and Africa and Europe are among some of the other prominent regions engaged in Premature Ovarian Failure-related drug trials.

Tongxiang Maternal and Child Health Hospital: The leading ongoing Premature Ovarian Failure related clinical trial sponsor

Tongxiang Maternal and Child Health Hospital is the top sponsor for Premature Ovarian Failure-related ongoing clinical trials.

Genesis Athens SA, Chinese Academy of Medical Sciences and Peking Union Medical College, Jiangsu Kanion Pharmaceutical Co Ltd, and Center for Human Reproduction are among other notable clinical trial sponsors involved in Premature Ovarian Failure. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Premature Ovarian Failure

Esterified estrogens (Menest), Estradiol Valerate (Progynon), and Conjugated estrogens (Premarin) are among the key marketed drugs involving Premature Ovarian Failure.

Esterified estrogens (Menest) is a mixture of the sodium salts of the sulfate esters of the estrogenic substances, principally estrone, excreted by pregnant mares. It functions via Estrogen Receptor (ESR) Agonist mechanism of action. It is formulated as tablet for oral administration. Menest is marketed for the treatment of Premature Ovarian Failure and several other indications including Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy), Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy), Metastatic Breast Cancer, Female Hypogonadism, Metastatic Prostate Cancer, and Vasomotor Symptoms of Menopause (Hot Flashes). Menest was first approved in 1977 and is marketed in the US by Pfizer Inc.

Estradiol Valerate (Progynon) is a natural and semisynthetic estrogen derivative, acts as reproductive agent. It functions via Estrogen Receptor (ESR) Agonist mechanism of action. It is formulated as powder for solution for intramuscular route of administration. Progynon is indicated for the treatment of amenorrhea, abnormal menstrual cycle (oligomenorrhea, multiple menstruation), abnormal menstrual flow, difficulty menstruation, functional uterine bleeding, uterine dysgenesis, ovarian deficiency and infertility. Progynon was first approved in 2008 and is marketed in Japan by Fuji Pharma Co Ltd.